Agios Pharmaceuticals Stock Forecast, Price & News

Agios Pharmaceuticals' stock was trading at $40.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AGIO shares have increased by 10.7% and is now trading at $45.25.
View which stocks have been most impacted by COVID-19.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Agios Pharmaceuticals or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Agios Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Agios Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Agios Pharmaceuticals.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) released its earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($1.43) earnings per share for the quarter, missing analysts' consensus estimates of ($1.36) by $0.07. The biopharmaceutical company had revenue of $34.70 million for the quarter, compared to the consensus estimate of $38.12 million. Agios Pharmaceuticals had a negative return on equity of 57.63% and a negative net margin of 170.65%. The business's revenue for the quarter was up 33.5% compared to the same quarter last year. During the same quarter last year, the business earned ($1.81) earnings per share.
View Agios Pharmaceuticals' earnings history.

12 analysts have issued 12 month price targets for Agios Pharmaceuticals' shares. Their forecasts range from $49.00 to $82.00. On average, they expect Agios Pharmaceuticals' share price to reach $68.00 in the next year. This suggests a possible upside of 50.3% from the stock's current price.
View analysts' price targets for Agios Pharmaceuticals.

Agios Pharmaceuticals saw a decline in short interest during the month of October. As of October 30th, there was short interest totaling 6,070,000 shares, a decline of 16.6% from the October 15th total of 7,280,000 shares. Based on an average daily volume of 689,600 shares, the days-to-cover ratio is presently 8.8 days.
View Agios Pharmaceuticals' Short Interest.

Some companies that are related to Agios Pharmaceuticals include Sarepta Therapeutics (SRPT), MyoKardia (MYOK), Mirati Therapeutics (MRTX), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Mylan (MYL), Galapagos (GLPG), Jazz Pharmaceuticals (JAZZ), Ultragenyx Pharmaceutical (RARE), Ionis Pharmaceuticals (IONS), Bausch Health Companies (BHC), Perrigo (PRGO) and Arrowhead Pharmaceuticals (ARWR).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), (CELG), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Agios Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.94%), State Street Corp (2.99%), First Trust Advisors LP (2.61%), ArrowMark Colorado Holdings LLC (1.56%), Point72 Asset Management L.P. (0.69%) and Morgan Stanley (0.64%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, Jacqualyn A Fouse, Scott Biller and Steven L Hoerter.
View institutional ownership trends for Agios Pharmaceuticals.

AGIO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., BNP Paribas Arbitrage SA, ExodusPoint Capital Management LP, Wells Fargo & Company MN, Equitable Holdings Inc., Peregrine Capital Management LLC, Charles Schwab Investment Management Inc., and Handelsbanken Fonder AB. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, and Christopher Bowden.
View insider buying and selling activity for Agios Pharmaceuticals.

AGIO stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Candriam Luxembourg S.C.A., First Trust Advisors LP, State Street Corp, Point72 Asset Management L.P., Cubist Systematic Strategies LLC, Squarepoint Ops LLC, and AXA S.A.. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, and Jacqualyn A Fouse.
View insider buying and selling activity for Agios Pharmaceuticals.

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AGIO stock can currently be purchased for approximately $45.25.

Agios Pharmaceuticals has a market capitalization of $3.13 billion and generates $117.91 million in revenue each year. The biopharmaceutical company earns $-411,470,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Agios Pharmaceuticals employs 536 workers across the globe.

The official website for Agios Pharmaceuticals is www.agios.com.

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]